Novartis's sales of Genmab-developed drug Kesimpta were better than both the analyst consensus estimate and Sydbank's prediction, which could mean an upgrade to its financial guidance is on the way from Genmab, Senior Analyst Søren Løntoft Hansen states.
Novartis released its Q3 report on Tuesday, revealing that net sales of its scleoris drug totaled USD 109m, which exceeds Sydbank's estimate of USD 90m. The consensus estimate of several analysts collected by Genmab itself was also USD 90m.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.
More from MedWatch
In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.